TERUMO CARDIOVASCULAR SYSTEMS CORPORATION VALVE, O.P.S BULK, N-S FOR TC; OVERPRESSURE SAFETY VALVE
|
Back to Search Results |
|
Model Number LN130BJ |
Device Problem
Leak/Splash (1354)
|
Patient Problem
No Clinical Signs, Symptoms or Conditions (4582)
|
Event Date 07/31/2023 |
Event Type
malfunction
|
Manufacturer Narrative
|
Terumo has not received the device for evaluation; therefore, the investigation has yet to be completed.Terumo plans on submitting a follow-up report when the investigation is complete and when more information becomes available.For this reason, terumo references evaluation conclusion code 11.Component code: 527- valve(s).Health effect ¿ impact.Code: 2199- no health consequences or impact health efect ¿ clinical code: 4582- no clinical signs, symptoms or conditions.Medical device problem code: 1354- leak/splash.Investigation findings: 3233 - results pending completion of investigation.Investigation conclusions: 11 - conclusion not yet available.
|
|
Event Description
|
The user facility reported to terumo cardiovascular that during cardiopulmonary bypass, there was a blood leakage.As per the subsidiary, blood leakage was noted from the ops valve in the suction line about 15 to 20 minutes after the pump was turned on.The ops valve was cut off and a straight connector (6 x 6) was connected to continue the surgery.No consequence or health impact to patient.Product was changed out.There were a few drops of blood loss 1 ml or less.Procedure was completed successfully.
|
|
Manufacturer Narrative
|
This follow-up report is submitted to fda in accord with applicable regulations.Upon further investigation of the reported event, the following information is new and/or changed: h6 (identification of evaluation codes 10, 3331, 213, 67).Type of investigation #1: 10 - testing of actual/suspected device.Type of investigation #2: 3331 - analysis of production records.Investigation findings: 213- no device problem found.Investigation conclusions: 67- no problem detected.The affected sample was inspected upon receipt with no anomalies noted.The ops valves are subject to a 100% leak test, which includes five different tests the units are run through to ensure there are no leaks and both the umbrellas and duckbills are functioning properly.The unit was then leak tested and passed all tests; it was found to function as intended and met all of the product specifications.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|
|
Event Description
|
Blood leakage.
|
|
Manufacturer Narrative
|
This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on august 23, 2023. upon further investigation of the reported event, the following information is new and/or changed: d9: (device availability - added date returned to manufacturer).G3: (date received by manufacturer).G6: (indication that this is a follow-up report).H2: (follow-up due to additional information).H3; (device evaluation anticipated by manufacturer - a second follow-up will be submitted upon completion of the investigation and/or submission of new information, thus tcvs references conclusions code 11. all available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|
|
Event Description
|
Blood leakage.
|
|
Search Alerts/Recalls
|
|
|